Posted by Michael Wonder on 02 Jul 2025
Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer
2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment of adults with advanced, KRAS G12C mutation positive non-small-cell lung cancer.
BMS will consider restarting this evaluation when the final overall survival analysis can be included in the modelled economic evaluation.
